CClinicalTrials.gg
RecruitingNCT06711783VISANUpdated May 1, 2026

Treatment of Adolescent Anorexia Nervosa

An interventional study of Family based therapy in Eating Disorders, sponsored by Region Örebro County. Recruiting at 1 site in Sweden. Open to participants aged 11 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Region Örebro County · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
11 Years to 17 Years
Sex
All
01

Study summary

VISAN is a naturalistic study of family based treatment of Anorexia nervosa in adolescnet girls.

02

Conditions studied

  • Eating Disorders

Keywords

  • anorexia nervosa
03

Who can participate

Ages eligible
11 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Having been diagnosed with f500 or f501 and being planned for family based therapy at the unit.

Exclusion criteria

Exclusion Criteria:

  • being subjected to care by the social welfare system
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Family based treatment

    Family based treatment including the whole chain of care, such as day care and in patiant care when necessary. The interventions includes consultation with dietician, psyciotherapist, LEAP-Y and Skills training based on an individual plan.

    Behavioral: Family based therapy

Interventions

  • BehavioralFamily based therapy

    Family based therapy following the Maudsley model

05

What researchers measure

Primary outcomes

  1. Remission

    No longer fulfilling criteria for an eating disorder

    Time frame: End of treatment (assessed up to 1 year)

06

Study locations

1 of 1 sites recruiting
07

Registry details

Key details

Study ID
NCT06711783
Lead sponsor
Region Örebro County
Responsible party
Sponsor
First posted
Dec 2, 2024
Start date
Aug 1, 2024
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
May 1, 2026

Study contacts

Sanna Gustafsson A Gustafsson, Ass prof
Contact
sanna.aila-gustafsson@regionorebrolan.se
+46722495986

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion